Christy M. Nance Net Worth

The estimated Net Worth of Christy M. Nance is at least $24 Thousand dollars as of 29 March 2018. Christy Nance owns over 50,000 units of Genprex Inc stock worth over $24,000 and over the last 7 years Christy sold GNPX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Christy Nance GNPX stock SEC Form 4 insiders trading

Christy has made over 1 trades of the Genprex Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Christy bought 50,000 units of GNPX stock worth $250,000 on 29 March 2018.

The largest trade Christy's ever made was buying 50,000 units of Genprex Inc stock on 29 March 2018 worth over $250,000. On average, Christy trades about 50,000 units every 0 days since 2018. As of 29 March 2018 Christy still owns at least 50,000 units of Genprex Inc stock.

You can see the complete history of Christy Nance stock trades at the bottom of the page.

What's Christy Nance's mailing address?

Christy's mailing address filed with the SEC is 8203 Scenic Ridge Cove, Austin, TX 78735, USA.

Insiders trading at Genprex Inc

Over the last 7 years, insiders at Genprex Inc have traded over $0 worth of Genprex Inc stock and bought 156,300 units worth $607,092 . The most active insiders traders include Ryan M. Confer, Christy M. Nance, and Jack A Roth. On average, Genprex Inc executives and independent directors trade stock every 205 days with the average trade being worth of $14,575. The most recent stock trade was executed by John Rodney Varner on 21 April 2023, trading 19,000 units of GNPX stock currently worth $20,140.

What does Genprex Inc do?

genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur

Complete history of Christy Nance stock trades at Genprex Inc

Genprex Inc executives and stock owners

Genprex Inc executives and other stock owners filed with the SEC include:

• Ryan Confer,
  Chief Financial Officer
• John Rodney Varner,
  Co, Founder, Pres, CEO, Sec. & Chairman
• J. Rodney Varner,
  Chairman of the Board, President, Chief Executive Officer, Secretary
• Catherine M. Vaczy,
  Exec. VP, Gen. Counsel & Chief Strategy Officer
• Catherine M. Vaczy Esq.,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer
• Ryan M. Confer M.S.,
  Chief Financial Officer
• William Wilson,
  Independent Director
• Jose Moreno Toscano,
  Independent Director
• Brent Longnecker,
  Independent Director
• Catherine Vaczy,
  Executive Vice President, Chief Strategy Officer
• Michael Redman,
  Chief Operating Officer, Executive Vice President
• David M. Schloss,
  Sr. VP of HR
• Greg Jancarik C.M.A., CPA, M.B.A.,
  Corp. Controller
• Dr. Mark S. Berger M.D.,
  Chief Medical Officer
• Dr. Hemant Kumar C.P.M., EMBA, Ph.D.,
  Chief Manufacturing & Technology Officer
• Dr. Jack A. Roth F.A.C.S., FACS, M.D.,
  Chairman of Scientific & Medical Advisory Board
• Dr. William E. Gannon Jr.,
  Member of Clinical Advisory Board & VP of Regulatory Affairs
• Thomas C. Gallagher Esq.,
  Sr. VP of Intellectual Property & Licensing
• Kalyn Dabbs,
  Sr. Mang. of Communications & Marketing
• Christy M. Nance,
  10% owner
• Jack A Roth,
  10% owner
• Viet An Hoan Ly,
  10% owner
• Inc. Genprex,,
  Chief Executive Officer
• Robert W. Pearson,
  Director
• David E. Friedman,
  Director
• Julien L Pham,
  President & COO
• Mark Stanley Berger,
  Chief Medical Officer
• Hermant Kumar,
  Chief Mfgr & Tech Officer